Less Than Half of Clinical Trials Report Results Within the Legally Required 12-Month Window, and the FDA Has Never Fined a Single Violator

Despite the Food and Drug Administration Amendments Act of 2007 (FDAAA) requiring clinical trial sponsors to report results on ClinicalTrials.gov within 12 months of study completion, only 1,722 out of 4,209 trials (41%) met this legal deadline. Thirty percent of trials remained completely unreported four years after completion, and the FDA has never imposed the statutory $10,000-per-day penalty for noncompliance. Why it matters: doctors and patients cannot see negative trial results that would change treatment decisions, so ineffective or harmful treatments continue to be prescribed based on incomplete evidence, so healthcare spending is wasted on interventions that unpublished trials already showed do not work, so new trials unknowingly duplicate failed studies because the failures were never disclosed, so human research subjects endure risks in redundant trials that could have been avoided if prior results had been public. The structural root cause is that the FDA has a structural conflict of interest: it depends on pharmaceutical company cooperation for drug approvals and post-market surveillance, so enforcing reporting penalties would antagonize the same companies it needs to regulate, while Congress has never mandated enforcement action or allocated dedicated resources for compliance monitoring.